Beyond Air announced the publication of its scientific article, “A safety evaluation of intermittent high-dose inhaled nitric oxide in viral pneumonia due to COVID-19: a randomized clinical study” in Scientific Reports, an online peer-reviewed journal from the publishers of Nature.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XAIR:
- Beyond Air® Publishes Peer-Reviewed Journal Article in Scientific Reports with Clinical Data Showing Nitric Oxide was Safe and Beneficial Adjunct Therapy for Subjects with Viral Pneumonia
- Beyond Air price target lowered to $3.50 from $7 at Piper Sandler
- Beyond Air cut 20% of workforce amid capital conservation strategy
- Beyond Air lowers 2025 revenue outlook to over $10M from $12M-$16M
- Beyond Air price target lowered to $4 from $19 at Ladenburg